Home/Filings/4/0001415889-24-008107
4//SEC Filing

ROCKLAGE SCOTT M 4

Accession 0001415889-24-008107

CIK 0001516551other

Filed

Mar 14, 8:00 PM ET

Accepted

Mar 15, 4:15 PM ET

Size

19.9 KB

Accession

0001415889-24-008107

Insider Transaction Report

Form 4
Period: 2024-03-13
PARMAR KUSH
10% Owner
Transactions
  • Purchase

    Common Stock

    2024-03-13$10.00/sh+450,000$4,500,0008,393,520 total(indirect: By 5AM Ventures VII, L.P.)
Holdings
  • Common Stock

    (indirect: By 5AM Ventures II, L.P.)
    1,718,189
  • Common Stock

    (indirect: By 5AM Co-Investors II, L.P.)
    67,796
Transactions
  • Purchase

    Common Stock

    2024-03-13$10.00/sh+450,000$4,500,0008,393,520 total(indirect: By 5AM Ventures VII, L.P.)
Holdings
  • Common Stock

    (indirect: By 5AM Co-Investors II, L.P.)
    67,796
  • Common Stock

    (indirect: By 5AM Ventures II, L.P.)
    1,718,189
Transactions
  • Purchase

    Common Stock

    2024-03-13$10.00/sh+450,000$4,500,0008,393,520 total(indirect: By 5AM Ventures VII, L.P.)
Holdings
  • Common Stock

    (indirect: By 5AM Ventures II, L.P.)
    1,718,189
  • Common Stock

    (indirect: By 5AM Co-Investors II, L.P.)
    67,796
Transactions
  • Purchase

    Common Stock

    2024-03-13$10.00/sh+450,000$4,500,0008,393,520 total(indirect: By 5AM Ventures VII, L.P.)
Holdings
  • Common Stock

    (indirect: By 5AM Ventures II, L.P.)
    1,718,189
  • Common Stock

    (indirect: By 5AM Co-Investors II, L.P.)
    67,796
Transactions
  • Purchase

    Common Stock

    2024-03-13$10.00/sh+450,000$4,500,0008,393,520 total(indirect: By 5AM Ventures VII, L.P.)
Holdings
  • Common Stock

    (indirect: By 5AM Co-Investors II, L.P.)
    67,796
  • Common Stock

    (indirect: By 5AM Ventures II, L.P.)
    1,718,189
Transactions
  • Purchase

    Common Stock

    2024-03-13$10.00/sh+450,000$4,500,0008,393,520 total(indirect: By 5AM Ventures VII, L.P.)
Holdings
  • Common Stock

    (indirect: By 5AM Ventures II, L.P.)
    1,718,189
  • Common Stock

    (indirect: By 5AM Co-Investors II, L.P.)
    67,796
Transactions
  • Purchase

    Common Stock

    2024-03-13$10.00/sh+450,000$4,500,0008,393,520 total(indirect: By 5AM Ventures VII, L.P.)
Holdings
  • Common Stock

    (indirect: By 5AM Co-Investors II, L.P.)
    67,796
  • Common Stock

    (indirect: By 5AM Ventures II, L.P.)
    1,718,189
Transactions
  • Purchase

    Common Stock

    2024-03-13$10.00/sh+450,000$4,500,0008,393,520 total(indirect: By 5AM Ventures VII, L.P.)
Holdings
  • Common Stock

    (indirect: By 5AM Ventures II, L.P.)
    1,718,189
  • Common Stock

    (indirect: By 5AM Co-Investors II, L.P.)
    67,796
Footnotes (3)
  • [F1]The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
  • [F2]The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
  • [F3]The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

Issuer

Skye Bioscience, Inc.

CIK 0001516551

Entity typeother

Related Parties

1
  • filerCIK 0001219014

Filing Metadata

Form type
4
Filed
Mar 14, 8:00 PM ET
Accepted
Mar 15, 4:15 PM ET
Size
19.9 KB